Tenaya Therapeutics (TNYA) Receivables - Other (2022)

Tenaya Therapeutics' (TNYA) quarterly Receivables - Other came in at $2.0 million in Q4 2022, little changed quarter-over-quarter from $2.0 million in Q2 2022.

Tenaya Therapeutics (TNYA) Receivables - Other (2022) Analysis & Trends

Tenaya Therapeutics' Receivables - Other history runs 1 years deep, the most recent figure standing at $2.0 million for Q4 2022.

  • On a quarterly basis, Receivables - Other changed N/A year-over-year to $2.0 million in Q4 2022; TTM through Dec 2022 was $2.0 million, a N/A change from a year earlier, with the FY2022 full-year figure at $2.0 million, changed N/A from the prior year.
  • Receivables - Other steadied at $2.0 million in Q4 2022 per TNYA's latest filing, from $2.0 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $2.0 million in Q2 2022 and bottomed at $2.0 million in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Tenaya Therapeutics 167.00 Mn 167.00 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2022 2.00 Mn
Dec 31, 2022 2.00 Mn
Jun 30, 2022 2.00 Mn
Jun 30, 2022 2.00 Mn